Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
$3.96
-$0.15(-7.18%)
At close: 4:00 PM EST
$3.96
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.05 - $5.19
Previous CloseN/A
Volume51.97K
Average Volume (3M)721.78K
Market Cap
$270.01M
Enterprise Value-$258.45K
Total Cash (Recent Filing)$86.90M
Total Debt (Recent Filing)$580.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 09, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding68,184,430
10 Day Avg. Volume1,217,427
30 Day Avg. Volume721,779
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.50Price Target Upside165.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesAnalyst notes multiple major clinical milestones expected in 2026, including Phase II readouts for budoprutug and initial human data for CLYM116 that could drive meaningful share upside.
Durable Efficacy And Mechanism ValidationAnalyst cites longer-term data showing durable proteinuria resolution with CD19-targeted budoprutug, reinforcing the view that the mechanism can deliver durable clinical benefit across autoimmune kidney diseases.
Formulation And AdministrationAnalyst highlights management confidence that budoprutug can be formulated for a pen-like auto-injector and that subcutaneous delivery could improve patient convenience and market adoption.
Bears Say
Enrollment RiskAnalyst warns that slow patient enrollment could reduce the number of participants included in updates, creating uncertainty about how complete and representative the results will be.
Limited Initial Data ContentAnalyst warns the initial Phase II update may include only the low-dose cohort and primarily pharmacodynamic markers, limiting evidence of clinical remission in the first readout.
Valuation And Comparability UncertaintyAnalyst notes the opportunity for CLYM116 in IgA nephropathy is not included in current valuation and that it is still early to draw direct comparisons between budoprutug and other late-stage programs, leaving upside and comparability uncertain.
Climb Bio News
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.05 and its highest was $5.19 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $270.01M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is Mar 09, 2026 which is in 52 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Nov 06, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.043.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate is -0.19.
How many shares outstanding does Climb Bio have?
Climb Bio has 68,184,430 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Climb Bio?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (165.15% Upside)
$10.50 (165.15% Upside)
Insider Transactions
Bought Shares
Worth $779.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-60.28%
12-Months-Change
Fundamentals
Return on Equity
-25.65%
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
Company Description
Climb Bio
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$10.50
▲(165.15% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
17.11% Insiders
2.88% Mutual Funds
56.39% Other Institutional Investors
21.14% Public Companies and Individual Investors
Options Prices
Currently, No data available
---